Patents by Inventor Curt Civin

Curt Civin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents
    Patent number: 9918972
    Abstract: Methods of treating cancer, such as leukemia, via administration of therapeutically effective amounts of artemisinins and second agents are detailed herein. The artemisinins include artesunate, dihydroartemisinin, artemether, arteether, artelinate, and ART-838. The second agents include BCL-2 inhibitors such as ABT-199, ABT-263, and ABT-737; kinase inhibitors such as lestaurtinib, midostaurin, and sorafenib; and anti-neoplastic agents such as cytarabine, doxorubicin, etoposide, cyclophosphamide, triplotide, vinorelbine, cisplatin, and rituximab.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: March 20, 2018
    Assignees: THE UNIVERSITY OF MARYLAND, BALTIMORE, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Curt Civin, Xiaochun Chen, Jennifer Fox, Gary Posner, Michelle Rudek
  • METHODS AND DEVICES FOR MULTI-STEP CELL PURIFICATION AND CONCENTRATION
    Publication number: 20170248508
    Abstract: Described herein are microfluidic devices and methods that can separate and concentrate particles in a sample.
    Type: Application
    Filed: May 15, 2017
    Publication date: August 31, 2017
    Inventors: Anthony WARD, Khushroo GANDHI, Alison SKELLEY, Curt CIVIN, James C. STURM, Lee AURICH, Michael GRISHAM, Joseph D'SILVA, Roberto CAMPOS-GONZALEZ, Robert H. Austin
  • TREATMENT OF LEUKEMIA WITH ARTEMISININ DERIVATIVES AND COMBINATIONS WITH OTHER ANTINEOPLASTIC AGENTS
    Publication number: 20160175331
    Abstract: Methods of treating cancer, such as leukemia, via administration of therapeutically effective amounts of artemisinins and second agents are detailed herein. The artemisinins include artesunate, dihydroartemisinin, artemether, arteether, artelinate, and ART-838. The second agents include BCL-2 inhibitors such as ABT-199, ABT-263, and ABT-737; kinase inhibitors such as lestaurtinib, midostaurin, and sorafenib; and anti-neoplastic agents such as cytarabine, doxorubicin, etoposide, cyclophosphamide, triplotide, vinorelbine, cisplatin, and rituximab.
    Type: Application
    Filed: December 23, 2015
    Publication date: June 23, 2016
    Applicant: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Curt CIVIN, Xiaochun Chen, Jennifer Fox, Gary Posner, Michelle Rudek
  • Therapeutic and diagnostic applications of genes differentially expressed in lympho-hematopoietic stem cells
    Publication number: 20070036765
    Abstract: The invention is based at least in part on the discovery of novel group of genes and/or their encoded gene products that are differentially represented in two substantially enriched CD34+/CD38?/Lin? and CD34+/[CD38/Lin]++ hematopoietic cell populations isolated from normal human bone marrow, cord blood, and peripheral blood stem cell preparations.
    Type: Application
    Filed: August 9, 2005
    Publication date: February 15, 2007
    Inventors: Curt Civin, Robert Georgantas